CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc.

1:15-cv-00109

Overview

Case Number 1:15-cv-00109
Filing Date 2015-06-26
Status Terminated
Termination Date 2017-09-12
Court District Court, N.D. West Virginia (wvnd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Plaintiff

Dr. Falk Pharma GmbH Operating Company

Represented By

8 Attorneys Listed

Counter Claimant

Counter Defendant

Salix Pharmaceuticals, Inc Operating Company

Represented By

8 Attorneys Listed

Court & Judges

Court

District Court, N.D. West Virginia (wvnd)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 3 proceedings
🏛️
USPTO PTAB Trials 3 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (6 found):
PTAB: 3 U.S. Courts: 3
USPTO PTAB Trial 2016-07-11
IPR2016-01409

MycoNovo, Inc. et al. v. Salix Pharmaceuticals, Ltd. et al.

Asserted Patent
Status: Terminated
USPTO PTAB Trial 2016-07-08
IPR2016-01386

Mylan Pharmaceuticals Inc. et al. v. Salix Pharmaceuticals, Ltd. et al.

Asserted Patent
Status: Terminated
USPTO PTAB Trial 2015-12-08
IPR2016-00297

GeneriCo, LLC et al. v. SALIX PHARMACEUTICALS, LTD. et al.

Asserted Patent
Status: Final Written Decision
U.S. District Court 2017-03-27
1:17-cv-00329

Salix Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-01-08
1:15-cv-00027

Salix Pharmaceuticals Inc. v. Novel Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-02-18
1:14-cv-00213

Salix Pharmaceuticals Inc. v. G & W Laboratories, Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8865688
Compositions and methods for treatment of bowel diseases with granulated mesalamine
Filed: 2009-10-02
Issued: 2014-10-21
Active (3.4 yrs remaining) +211d PTA
Expires: 2030-05-01

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+211 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

61

Dispositive

0

Granted

25

Denied

0

Pending / Review

33

Motions by Category

Procedural / Extension Motion 48 Claim Construction / Markman Filing 13

Key Dispositive Motions & Rulings

Procedural / Extension Motion Granted
ORDER GRANTING 273 JOINT MOTION TO EXTEND TIME REGARDING BILL OF COSTS. Signed by Senior Judge Irene M. Keeley on 12/27/17. (njz) (Entered: 12/27/2017)
Entry #274 • 2017-12-27 Document →
Procedural / Extension Motion Granted
Joint MOTION for Extension of Time to File Bill of Costs by Mylan Pharmaceuticals, Inc., Mylan, Inc.. (Attachments: # 1 Text of Proposed Order)(O'Brien, William...
Entry #273 • 2017-12-22 Document →
Procedural / Extension Motion Granted
ORDER granting James C. Grant's 213 Motion for Leave to Appear pro hac vice. Signed by District Judge Irene M. Keeley on 5/1/17. (jss) (Entered: 05/01/2017)
Entry #219 • 2017-05-01 Document →
Procedural / Extension Motion Granted
ORDER granting Joseph M. Janusz's 210 Motion for Leave to Appear pro hac vice. Signed by District Judge Irene M. Keeley on 5/1/17. (jss) (Entered: 05/01/2017)
Entry #220 • 2017-05-01 Document →
Procedural / Extension Motion Granted
ORDER granting Deepro Mukerjee's 211 Motion for Leave to Appear pro hac vice. Signed by District Judge Irene M. Keeley on 5/1/17. (jss) (Entered: 05/01/2017)
Entry #221 • 2017-05-01 Document →
Procedural / Extension Motion Granted
ORDER granting Lance Soderstrom's 212 Motion for Leave to Appear pro hac vice. Signed by District Judge Irene M. Keeley on 5/1/17. (jss) (Entered: 05/01/2017)
Entry #222 • 2017-05-01 Document →

Docket Entries

(287 total)
Pleading / Complaint

COMPLAINT for Patent Infringement against Mylan Pharmaceuticals, Inc., Mylan, Inc., filed by Salix Pharmaceuticals, Inc, Dr. Falk Pharma GmbH. (Attachments: # 1 Exhibit A - US Patent, # 2 Exhibit B - US Patent, # 3 Exhibit C - US Patent, # 4 Exhibit D - US Patent, # 5 Supplemental Information, # 6 Civil Cover Sheet)(cnd) (Entered: 06/26/2015)

Entry #1 • 2015-06-26
1

Filing fee: $ 400.00, receipt number WVNW001184. (cnd) (Entered: 06/26/2015)

Entry #2 • 2015-06-26
1
Pleading / Complaint

REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (cnd) (Entered: 06/26/2015)

Entry #3 • 2015-06-26
1

Corporate Disclosure Statement by Dr. Falk Pharma GmbH, Salix Pharmaceuticals, Inc identifying Corporate Parent Salix Pharmaceuticals, Ltd., Corporate Parent Valeant Pharmaceuticals International, Corporate Parent Valeant Pharmaceuticals International, Inc. for Salix Pharmaceuticals, Inc.. (cnd) (Entered: 06/26/2015)

Entry #5 • 2015-06-26
1
Pleading / Complaint

VERIFICATION OF ATTORNEY ADMISSION as to Dana Severance, Daniel Attaway, Kristen Cramer, Mary Bourke, and Tryn Stimart re 1 Complaint. (cnd) (Entered: 07/01/2015)

Entry #6 • 2015-07-01
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc